Cited by 361Antifungal resistance and susceptibilityBacterial Identification and Susceptibility TestingFungal Infections and Studies

The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.

Has antifungal susceptibility testing come of age

Rex, John H., Pfaller, Michael A.·2002·Clinical Infectious Diseases

DOI 10.1086/342384

Open this paper in CoChat — free account

Abstract

The in vitro susceptibility of an infecting organism to the antimicrobial agent selected for therapy is one of several factors that influence the likelihood that therapy for an infection will be successful. To appreciate the value of antifungal susceptibility testing, it is helpful to review the overall predictive utility of antibacterial susceptibility testing. After >30 years of study, in vitro susceptibility can be said to predict the response of bacterial infections with an accuracy that is well summarized as the "90-60 rule": infections due to susceptible isolates respond to therapy approximately 90% of the time, whereas infections due to resistant isolates respond approximately 60% of the time. On the basis of a growing body of knowledge, standardized susceptibility testing for selected organism-drug combinations (most notably, Candida species and the azole antifungal agents) has been shown to have similar predictive utility. Antifungal susceptibility testing is now increasingly and appropriately used as a routine adjunct to the treatment of fungal infections.

Integrity signals

Registry

Crossref · 10.1086/342384

Cites

64 of 64 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

State‐of‐the‐Art Clinical Article: Pharmacokinetic/Pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men
Craig, W. A. (1998) · Clinical Infectious Diseases · doi:10.1086/516284 · Cited by 2,908
The Clinical Significance of Positive Blood Cultures in the 1990s: A Prospective Comprehensive Evaluation of the Microbiology, Epidemiology, and Outcome of Bacteremia and Fungemia in Adults
Weinstein, M. P., Towns, M., Quartey, S. M., Mirrett, S., Reimer, L. G., Parmigiani, G., & Reller, L. B. (1997) · Clinical Infectious Diseases · doi:10.1093/clind/24.4.584 · Cited by 1,225
Clinical Response to Aminoglycoside Therapy: Importance of the Ratio of Peak Concentration to Minimal Inhibitory Concentration
Moore, R. D., Lietman, P. S., & Smith, C. R. (1987) · The Journal of Infectious Diseases · doi:10.1093/infdis/155.1.93 · Cited by 1,143
Current and emerging azole antifungal agents
Sheehan, D. J., Hitchcock, C. A., & Sibley, C. M. (1999) · Clinical Microbiology Reviews · doi:10.1128/cmr.12.1.40 · Cited by 1,137
Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients
Forrest, A., Nix, D. E., Ballow, C. H., Goss, T. F., Birmingham, M. C., & Schentag, J. J. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.5.1073 · Cited by 1,101
Anthrax
Dixon, T. C., Meselson, M. S., Guillemin, J. H., & Hanna, P. C. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909093411107 · Cited by 871
Development of Interpretive Breakpoints for Antifungal Susceptibility Testing: Conceptual Framework and Analysis of In Vitro-In Vivo Correlation Data for Fluconazole, Itraconazole, and Candida Infections
Rex, J. H., Pfaller, M. A., Galgiani, J. N., Bartlett, M. S., Espinel-Ingroff, A., Ghannoum, M. A., Lancaster, M., Odds, F. C., Rinaldi, M. G., Walsh, T. J., et al. (1997) · Clinical Infectious Diseases · doi:10.1093/clinids/24.2.235 · Cited by 855
Self-citation
The Clinical Significance of Positive Blood Cultures: A Comprehensive Analysis of 500 Episodes of Bacteremia and Fungemia in Adults. II. Clinical Observations, with Special Reference to Factors Influencing Prognosis
Weinstein, M. P., Murphy, J. R., Reller, L. B., & Lichtenstein, K. A. (1983) · Clinical Infectious Diseases · doi:10.1093/clinids/5.1.54 · Cited by 471
Antifungal Susceptibility Testing: Practical Aspects and Current Challenges
Rex, J. H., Pfaller, M. A., Walsh, T. J., Chaturvedi, V., Espinel-Ingroff, A., Ghannoum, M. A., Gosey, L. L., Odds, F. C., Rinaldi, M. G., Sheehan, D. J., et al. (2001) · Clinical Microbiology Reviews · doi:10.1128/cmr.14.4.643-658.2001 · Cited by 444
Self-citation
In Vitro Activity of the New Triazole Voriconazole (UK-109,496) against Opportunistic Filamentous and Dimorphic Fungi and Common and Emerging Yeast Pathogens
Espinel-Ingroff, A. V. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.1.198-202.1998 · Cited by 357
Trichosporon beigelii, an emerging pathogen resistant to amphotericin B
Walsh, T. J., MELCHER, G. P., Rinaldi, M. G., Lecciones, J., McGough, D. A., Kelly, P. M., Lee, J. K., Callender, D. P., Rubin, M., & Pizzo, P. A. (1990) · Journal of Clinical Microbiology · doi:10.1128/jcm.28.7.1616-1622.1990 · Cited by 310
Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia. NIAID Mycoses Study Group and the Candidemia Study Group
Rex, J. H., Pfaller, M. A., Barry, A. L., Nelson, P. W., & Webb, C. D. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.40 · Cited by 300
Self-citation
Introduction to Antifungal Drugs
Dismukes, W. E. (2000) · Clinical Infectious Diseases · doi:10.1086/313748 · Cited by 262
In Vitro Amphotericin B Resistance in Clinical Isolates of Aspergillus terreus , with a Head-to-Head Comparison to Voriconazole
Sutton, D. A., Sanche, S. E., Revankar, S. G., Fothergill, A. W., & Rinaldi, M. G. (1999) · Journal of Clinical Microbiology · doi:10.1128/jcm.37.7.2343-2345.1999 · Cited by 254
Evolving Role of Flucytosine in Immunocompromised Patients: New Insights into Safety, Pharmacokinetics, and Antifungal Therapy
Francis, P., & Walsh, T. J. (1992) · Clinical Infectious Diseases · doi:10.1093/clind/15.6.1003 · Cited by 232
In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis
Lass‐Flörl, C., Kofler, G., Kropshofer, G., Hermans, J., Kreczy, A., Dierich, M. P., & Niederwieser, D. W. (1998) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/42.4.497 · Cited by 223
Do In Vitro Susceptibility Data Predict the Microbiologic Response to Amphotericin B? Results of a Prospective Study of Patients with Candida Fungemia
Nguyen, M. H., Clancy, C. J., Yu, V. L., Yu, Y. C., Morris, A. J., Snydman, D. R., Sutton, D. A., & Rinaldi, M. G. (1998) · The Journal of Infectious Diseases · doi:10.1086/514193 · Cited by 219
Antimicrobial Resistance and Clinical Outcome of Bacteroides Bacteremia: Findings of a Multicenter Prospective Observational Trial
Nguyen, M. H., Yu, V. L., Morris, A. J., McDermott, L. A., Wagener, M. W., Harrell, L. J., & Snydman, D. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313805 · Cited by 215
Deep Infections Caused by Scedosporium prolificans: A Report on 16 Cases in Spain and a Review of the Literature
Berenguer, J., Rodrı́guez-Tudela, J. L., Richard, C., Alvarez, M., Sanz, M. Á., Gaztelurrutia, L., Ayats, J., & Martı́nez-Suárez, J. V. (1997) · Medicine · doi:10.1097/00005792-199707000-00004 · Cited by 213
Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for antifungal susceptibility testing: enhanced ability to detect amphotericin B-resistant Candida isolates
Wanger, A., Mills, K., Nelson, P. W., & Rex, J. H. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.11.2520 · Cited by 202
Self-citation
Detection of amphotericin B-resistant Candida isolates in a broth-based system
Rex, J. H., Cooper, C. R., Merz, W. G., Galgiani, J. N., & Anaissie, E. J. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.4.906 · Cited by 198
Self-citation
Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model
Andes, D., & van Ogtrop, M. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.9.2116 · Cited by 192
Correlation of Fluconazole MICs with Clinical Outcome in Cryptococcal Infection
Aller, A. I., Martín‐Mazuelos, E., Lozano, F., Gómez-Mateos, J. M., Steele‐Moore, L., Holloway, W. J., Gutiérrez, M. J., Recio, F., & Espinel-Ingroff, A. V. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.6.1544-1548.2000 · Cited by 171
Antifungal Drug Resistance in Aspergillus
Moore, C. B., Sayers, N. M., Mosquera, J., Slaven, J. W., & Denning, D. W. (2000) · Journal of Infection · doi:10.1053/jinf.2000.0747 · Cited by 162
In Vitro Activities of Posaconazole (Sch 56592) Compared with Those of Itraconazole and Fluconazole against 3,685 Clinical Isolates of Candida spp. and Cryptococcus neoformans
Pfaller, M. A., Messer, S. A., Hollis, R. J., & Jones, R. N. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.10.2862-2864.2001 · Cited by 144
Self-citation
Activities of amphotericin B and antifungal azoles alone and in combination against Pseudallescheria boydii
Walsh, T. J., Peter, J., McGough, D. A., Fothergill, A. W., Rinaldi, M. G., & Pizzo, P. A. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.6.1361 · Cited by 138
Identification of Patients with Acute AIDS-Associated Cryptococcal Meningitis Who Can Be Effectively Treated with Fluconazole: The Role of Antifungal Susceptibility Testing
Witt, M. D., Lewis, R. J., Larsen, R. A., Milefchik, E. N., Leal, M. A. E., Haubrich, R., Richie, J., Edwards, J. E., & Ghannoum, M. A. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/22.2.322 · Cited by 136
Bacteriologic Efficacies of Oral Azithromycin and Oral Cefaclor in Treatment of Acute Otitis Media in Infants and Young Children
Dagan, R., Leibovitz, E., Fliss, D. M., Leiberman, A., Jacobs, M. R., Craig, W. A., & Yagupsky, P. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.1.43-50.2000 · Cited by 134
In Vitro Veritas? Antimicrobial Susceptibility Tests and Their Clinical Relevance
Greenwood, D. (1981) · The Journal of Infectious Diseases · doi:10.1093/infdis/144.4.380 · Cited by 117
Bacteriologic Response to Oral Cephalosporins: Are Established Susceptibility Breakpoints Appropriate in the Case of Acute Otitis Media?
Dagan, R., Abramson, O., Liebovitz, E., Greenberg, D., Lang, R., Goshen, S., Yagupsky, P., Leiberman, A., & Fliss, D. M. (1997) · The Journal of Infectious Diseases · doi:10.1086/514120 · Cited by 110
Detection of Resistance to Amphotericin B among Cryptococcus neoformans Clinical Isolates: Performances of Three Different Media Assessed by Using E-Test and National Committee for Clinical Laboratory Standards M27-A Methodologies
Lozano‐Chiu, M., Paetznick, V. L., Ghannoum, M. A., & Rex, J. H. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2817-2822.1998 · Cited by 106
Self-citation
In Vivo Characterization of the Pharmacodynamics of Flucytosine in a Neutropenic Murine Disseminated Candidiasis Model
Andes, D. R., & van Ogtrop, M. L. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.4.938-942.2000 · Cited by 96
Emergence of Resistance to Fluconazole as a Cause of Failure during Treatment of Histoplasmosis in Patients with Acquired Immunodeficiency Disease Syndrome
Wheat, L. J., Connolly, P., Smedema, M. L., Brizendine, E. J., & Hafner, R. (2001) · Clinical Infectious Diseases · doi:10.1086/323781 · Cited by 96
High-Frequency, In Vitro Reversible Switching of Candida lusitaniae Clinical Isolates from Amphotericin B Susceptibility to Resistance
Yoon, S. A., Vázquez, J. A., Steffan, P. E., Sobel, J. D., & Akins, R. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.4.836 · Cited by 90
In vivo correlates for Streptococcus pneumoniae penicillin resistance in acute otitis media
Géhanno, P., Lenoir, G., & Berche, P. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.1.271 · Cited by 90
Correlation between In Vitro Susceptibility Determined by E Test and Response to Therapy with Amphotericin B: Results from a Multicenter Prospective Study of Candidemia
Clancy, C. J., & Nguyen, M. H. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.5.1289 · Cited by 89
Improved Detection of Amphotericin B-Resistant Isolates of Candida lusitaniae by Etest
Peyron, F., Favel, A., Michel-Nguyen, A., Gilly, M., Regli, P., & Bolmström, A. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.339-342.2001 · Cited by 87
Clinical Correlates of Antifungal Macrodilution Susceptibility Test Results for Non-AIDS Patients with Severe Candida Infections Treated with Fluconazole
Lee, S.-C., Fung, C., Huang, J., Tsai, C.-J., Chen, K.-S., Chen, H.-Y., Lee, N., See, L., & Wb, S. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2715-2718.2000 · Cited by 81
Correlation of in-vitro susceptibility test results with clinical response: a study of azole therapy in AIDS patients
Rodrı́guez-Tudela, J. L., MartinezSuárez, J., Dronda, F., Laguna, F., Cháves, F., & Valencia, E. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/35.6.793 · Cited by 76
Flucytosine Monotherapy for Cryptococcosis
Hospenthal, D. R., & Bennett, J. E. (1998) · Clinical Infectious Diseases · doi:10.1086/514669 · Cited by 75
Use of Pharmacodynamic Indices To Predict Efficacy of Combination Therapy In Vivo
Mouton, J. W., van Ogtrop, M. L., Andes, D. R., & Craig, W. A. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.10.2473 · Cited by 74
In vitro antifungal activity of posaconazole against various pathogenic fungi
Uchida, K., Yokota, N., & Yamaguchi, H. (2001) · International Journal of Antimicrobial Agents · doi:10.1016/s0924-8579(01)00363-6 · Cited by 68
Efficacy of amoxicillin/clavulanate for acute otitis media: relation to Streptococcus pneumoniae susceptibility
Hoberman, A., Paradise, J. L., Block, S. L., BURCH, D. J., Jacobs, M. R., & BALANESCU, M. I. (1996) · The Pediatric Infectious Disease Journal · doi:10.1097/00006454-199610000-00034 · Cited by 61
In Vitro Activities of Terbinafine against Aspergillus Species in Comparison with Those of Itraconazole and Amphotericin B
Moore, C. B., Walls, C. M., & Denning, D. W. (2001) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.45.6.1882-1885.2001 · Cited by 57
Predictive value of susceptibility tests for the outcome of antibacterial therapy
Lorian, V., & Burns, L. (1990) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/25.1.175 · Cited by 50
Discrepancies between in vitro activity of and in vivo response to antimicrobial agents
Washington, J. A. (1983) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/0732-8893(83)90029-9 · Cited by 49
Fluconazole Susceptibility Testing of Cryptococcus neoformans : Comparison of Two Broth Microdilution Methods and Clinical Correlates among Isolates from Ugandan AIDS Patients
Jessup, C. J., Pfaller, M. A., Messer, S. A., Zhang, J., Tumberland, M., Mbidde, E. K., & Ghannoum, M. A. (1998) · Journal of Clinical Microbiology · doi:10.1128/jcm.36.10.2874-2876.1998 · Cited by 46
Self-citation
Amphotericin B resistance testing of Candida spp.: a comparison of methods
Law, D. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.109 · Cited by 44
European standards for antibiotic susceptibility testing: Towards a theoretical consensus
Baquero, F. (1990) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/bf01964289 · Cited by 39
Timed-kill curves for Cryptococcus neoformans isolated from patients with AIDS
Rodero, L., Córdoba, S. B., Cahn, P. E., Soria, M., Lucarini, M., Davel, G., Kaufman, S. C., Canteros, C. E., & Guelfand, L. I. (2000) · Medical Mycology · doi:10.1080/mmy.38.3.201.207 · Cited by 37
Patterns of in vitro activity of itraconazole and imidazole antifungal agents against Candida albicans with decreased susceptibility to fluconazole from Spain
Martı́nez-Suárez, J. V., & Rodríguez-Tudela, J. L. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.7.1512 · Cited by 35
Azole resistance among oral Candida species isolates from AIDS patients under ketoconazole exposure
Milan, E. P., Burattini, M. N., Kallas, E. G., Fischmann, O., Costa, P. R. D. O., & Colombo, A. L. (1998) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/s0732-8893(98)00107-2 · Cited by 32
In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy
Rodero, L., Córdoba, S. B., Cahn, P. E., Hochenfellner, F., Davel, G., Canteros, C. E., Kaufman, S. C., & Guelfand, L. I. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.2.239 · Cited by 30
Oropharyngeal Candidiasis in Patients with Human Immunodeficiency Virus: Correlation of Clinical Outcome with In Vitro Resistance, Serum Azole Levels, and Immunosuppression
Walmsley, S. L., King, S., McGeer, A., Ye, Y., & Richardson, S. E. (2001) · Clinical Infectious Diseases · doi:10.1086/320517 · Cited by 29
Correlation of In Vitro Fluconazole Susceptibility with Clinical Outcome for Severely Ill Patients with Oropharyngeal Candidiasis
Arıkan, S., Akova, M., Hayran, M., Özdemir, O., Erman, M., Gür, D., & Ünal, S. (1998) · Clinical Infectious Diseases · doi:10.1086/513927 · Cited by 27
Ketoconazole and itraconazole susceptibility of Candida albicans isolated from patients infected with HIV
St-Gennain, G., Dion, C., Espinel‐Ingroff, A., Ratelle, J., & de Repentigny, L. (1995) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/36.1.109 · Cited by 25
Unresponsive HIV-related oro-oesophageal candidosis--an evaluation of two new in-vitro azole susceptibility tests
Cartledge, J. D., Midgley, J., Petrou, M. A., Shanson, D. C., & Gazzard, B. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.4.517 · Cited by 22
ARTs versns ASTs: where are we going?
Sanders, C. C. (1991) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/28.5.621 · Cited by 17
Antimicrobial Susceptibility Tests: Testing Methods and Interpretive Problems
Murray, P. R. (1994) · Advances in experimental medicine and biology · doi:10.1007/978-1-4757-9206-5_3 · Cited by 16
Interpretive criteria for in vitro antimicrobial susceptibility tests
Doern, G. V. (1995) · Reviews in Medical Microbiology · doi:10.1097/00013542-199504000-00006 · Cited by 8
Antimicrobial susceptibility testing: Critical issues for the 90s
(1995) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(95)90067-5 · Cited by 5
Interpretive guidelines for antimicrobial susceptibility test results: What do they mean?
Hindler, J. A., & Thrupp, L. D. (1989) · Clinical Microbiology Newsletter · doi:10.1016/0196-4399(89)90019-6 · Cited by 5
Discrepancies between in vitro activity of and in vivo response to antimicrobial agents
Welsby, P. D. (1985) · Journal of Infection · doi:10.1016/s0163-4453(85)93822-8 · Cited by 4
Clinical predictive value of in vitro susceptibility tests
Murray, P. R. (1990) · Clinical Microbiology Newsletter · doi:10.1016/0196-4399(90)90071-i · Cited by 4

Flagged first, then by citations

Sorted by citations

Epidemiology of Invasive Candidiasis: a Persistent Public Health Problem
Pfaller, M. A., & Diekema, D. J. (2007) · Clinical Microbiology Reviews · doi:10.1128/cmr.00029-06 · Cited by 4,174
Self-citation
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440
Self-citation
Epidemiology of Invasive Mycoses in North America
Pfaller, M. A., & Diekema, D. J. (2010) · Critical Reviews in Microbiology · doi:10.3109/10408410903241444 · Cited by 901
Self-citation
Increasing Echinocandin Resistance in Candida glabrata: Clinical Failure Correlates With Presence of FKS Mutations and Elevated Minimum Inhibitory Concentrations
Alexander, B. D., Johnson, M. D., Pfeiffer, C. D., Jiménez-Ortigosa, C., Catania, J., Booker, R., Castanheira, M., Messer, S. A., Perlin, D. S., & Pfaller, M. A. (2013) · Clinical Infectious Diseases · doi:10.1093/cid/cit136 · Cited by 778
Self-citation
Incidence of Bloodstream Infections Due to Candida Species and In Vitro Susceptibilities of Isolates Collected from 1998 to 2000 in a Population-Based Active Surveillance Program
Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., et al. (2004) · Journal of Clinical Microbiology · doi:10.1128/jcm.42.4.1519-1527.2004 · Cited by 649

See all 361

Authors: Rex, J. H., & Pfaller, M. A.
Affiliations: Texas Medical Center (US)
University of Iowa (US)
Corresponding author: Rex, John H.
ORCID: Rex, John H.
Pfaller, Michael A.
Venue: Clinical Infectious Diseases
Publisher: Oxford University Press (OUP)
Published: 2002-10-15
Volume: 35
Issue: 8
Pages: 982-989
ISSN: 1058-4838 (ISSN-L)
1537-6591
DOI: 10.1086/342384
OpenAlex: W2118836068
Cited by: 361
References: 64
Citations by year: 2026: 5 · 2025: 5 · 2024: 10 · 2023: 11 · 2022: 13 · 2021: 8 · 2020: 17 · 2019: 10 · 2018: 16 · 2017: 21 · 2016: 13 · 2015: 14 · 2014: 24 · 2013: 17 · 2012: 14
FWCI: 10.38
Type: journal article
Language: en
Open access: closed
Locations: Clinical Infectious Diseases (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
Health Sciences › Medicine › Microbiology (medical) › Bacterial Identification and Susceptibility Testing
Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
Keywords: antifungal susceptibility testing, in vitro susceptibility, predictive utility, antifungal resistance, Candida species, azole antifungals, fungal infection, treatment response
MeSH terms: Amphotericin B, Antifungal Agents, Azoles, Candida, Clinical Trials as Topic, Flucytosine, Humans, Microbial Sensitivity Tests, Statistics as Topic

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Has antifungal susceptibility testing come of age

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks